Valeant Pharmaceuticals International Inc, which is pursuing a hostile takeover offer for Allergan Inc, on Monday said it expects sales to rise 15 percent in the third quarter but will face a tougher fourth-quarter comparison to year-ago results. Valeant, which completed the $8.7 billion purchase of Bausch & Lomb on Aug. 6, 2013, said its third-quarter sales reflect a weak year-ago period for the contact lens maker.The Canadian company did not give a specific fourth-quarter forecast.Allergan, the maker of Botox anti-wrinkle injections, has criticized Valeant's acquisition-based business model as it attempts to fend off the drugmaker's $51 billion hostile bid.
Allergan, Inc. is a multi-specialty health care Company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products. Shares of AGN traded higher by 0.96% or $1.7/share to $179.70. In the past year, the shares have traded as low as $88.34 and as high as $179.59. On average, 1951950 shares of AGN exchange hands on a given day and today's volume is recorded at 2260112.
Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Shares of VRX traded higher by 0.98% or $1.27/share to $130.26. In the past year, the shares have traded as low as $102.60 and as high as $153.10. On average, 2537910 shares of VRX exchange hands on a given day and today's volume is recorded at 2663223.
Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Shares of VRX traded higher by 0.25% or $0.36/share to $144.67. In the past year, the shares have traded as low as $105.77 and as high as $170.45. On average, 392158 shares of VRX.TO exchange hands on a given day and today's volume is recorded at 616786.
Source
